DE60002607D1 - Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan - Google Patents

Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan

Info

Publication number
DE60002607D1
DE60002607D1 DE60002607T DE60002607T DE60002607D1 DE 60002607 D1 DE60002607 D1 DE 60002607D1 DE 60002607 T DE60002607 T DE 60002607T DE 60002607 T DE60002607 T DE 60002607T DE 60002607 D1 DE60002607 D1 DE 60002607D1
Authority
DE
Germany
Prior art keywords
carnitine
chitosan
composition
preventing
disturbances due
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60002607T
Other languages
English (en)
Other versions
DE60002607T2 (de
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau HealthScience SpA
Original Assignee
Sigma Tau HealthScience SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau HealthScience SpA filed Critical Sigma Tau HealthScience SpA
Application granted granted Critical
Publication of DE60002607D1 publication Critical patent/DE60002607D1/de
Publication of DE60002607T2 publication Critical patent/DE60002607T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60002607T 1999-11-18 2000-11-14 Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan Expired - Lifetime DE60002607T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999RM000707A IT1307278B1 (it) 1999-11-18 1999-11-18 Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
ITRM990707 1999-11-18
PCT/IT2000/000462 WO2001035944A2 (en) 1999-11-18 2000-11-14 Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan

Publications (2)

Publication Number Publication Date
DE60002607D1 true DE60002607D1 (de) 2003-06-12
DE60002607T2 DE60002607T2 (de) 2004-03-18

Family

ID=11407056

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60002607T Expired - Lifetime DE60002607T2 (de) 1999-11-18 2000-11-14 Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan

Country Status (19)

Country Link
US (2) US6780851B1 (de)
EP (1) EP1233788B1 (de)
AT (1) ATE239504T1 (de)
AU (1) AU782178C (de)
CA (1) CA2391625C (de)
CZ (1) CZ20021564A3 (de)
DE (1) DE60002607T2 (de)
DK (1) DK1233788T3 (de)
ES (1) ES2197890T3 (de)
HU (1) HU229365B1 (de)
IL (1) IL149619A0 (de)
IT (1) IT1307278B1 (de)
MX (1) MXPA02004987A (de)
NO (1) NO20022288L (de)
PL (1) PL204745B1 (de)
PT (1) PT1233788E (de)
SK (1) SK6982002A3 (de)
TN (1) TNSN00216A1 (de)
WO (1) WO2001035944A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
ITRM20010044A1 (it) * 2001-01-29 2002-07-29 Sigma Tau Healthscience Spa Integratore alimentare ad effetto dimagrante.
FR2900054B1 (fr) * 2006-04-21 2012-09-28 Kitozyme Sa Utilisation de polysaccharides d'origine fongique comme composition pharmaceutique ou complements alimentaires pour la sante humaine et animale
US7052722B2 (en) * 2003-12-01 2006-05-30 Cj Corp. Composition for weight reduction comprising water-soluble low-molecular weight chitosan and Hibiscus extract
MXPA05014089A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias inhibidoras de la recaptura de noradrenalina, dopamina y serotonina, combinadas con un aminoacido para el tratamiento de la obesidad y sobrepeso.
ITRM20060204A1 (it) 2006-04-10 2007-10-11 Vincenzo Savica Farmaci e alimentei per diete normoproteiche iperproteiche ipopro teiche tutte ipofosforiche e bevande ipofosforiche
WO2013108263A1 (en) 2012-01-18 2013-07-25 Zota Health Care Ltd Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality
CN105326053A (zh) * 2015-10-03 2016-02-17 王保红 含有左旋肉碱与壳寡糖的组合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
JP3108675B2 (ja) * 1998-03-17 2000-11-13 阪急共栄物産株式会社 脂質代謝改善剤
EP0951909B2 (de) * 1998-03-19 2010-10-20 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Kombinierte Zusammensetzung bestehend aus L-Karnitin oder L-Alkanoylkarnitin, einem Glycosaminoglycan und/oder einem seiner Bestandteile
AU747611B2 (en) * 1998-07-30 2002-05-16 E-Nutriceuticals, Inc. Novel chitosan-containing liquid compositions and methods for their preparation and use

Also Published As

Publication number Publication date
PL356183A1 (en) 2004-06-14
NO20022288D0 (no) 2002-05-14
HU229365B1 (hu) 2013-11-28
SK6982002A3 (en) 2002-09-10
AU782178B2 (en) 2005-07-07
PT1233788E (pt) 2003-09-30
US20050020538A1 (en) 2005-01-27
WO2001035944A2 (en) 2001-05-25
NO20022288L (no) 2002-05-14
IT1307278B1 (it) 2001-10-30
HUP0203379A2 (hu) 2003-02-28
WO2001035944A3 (en) 2002-02-07
CA2391625C (en) 2009-06-30
EP1233788A2 (de) 2002-08-28
US8198260B2 (en) 2012-06-12
ITRM990707A1 (it) 2001-05-18
ATE239504T1 (de) 2003-05-15
CA2391625A1 (en) 2001-05-25
AU782178C (en) 2006-08-10
US6780851B1 (en) 2004-08-24
HUP0203379A3 (en) 2003-12-29
DK1233788T3 (da) 2003-09-01
TNSN00216A1 (fr) 2005-11-10
CZ20021564A3 (cs) 2002-11-13
ES2197890T3 (es) 2004-01-16
PL204745B1 (pl) 2010-02-26
AU1885101A (en) 2001-05-30
DE60002607T2 (de) 2004-03-18
EP1233788B1 (de) 2003-05-07
ITRM990707A0 (it) 1999-11-18
MXPA02004987A (es) 2003-01-28
IL149619A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
WO2000011968A8 (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
CA2334875A1 (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome
DE69622035D1 (de) Örtliche behandlung und vorbeugung des durchhängens subkutaner muskel und des darüberliegenden hautgewebes unter verwendung von acetylcholinvorstufen und catecholaminen
CA2529735A1 (en) Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities
TR200003736T2 (tr) Anksiyete durumlarına ya da depresyona bağlı değişikliklerin önlenmesi
BRPI0416809A (pt) glicosamina
BR0014262A (pt) Preparação antioxidante com base em extratos vegetais para o tratamento de problemas de adiposidade e circulatórios
BR0307126A (pt) Uso de beldroega para tratar rugas faciais
DE60002607D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
HUP0203449A2 (hu) L-karnitin-számazékokat és ginkgo biloba kivonatot tartalmazó készítmény keringési rendellenességek megelőzésére és/vagy kezelésére
DE69826674D1 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
KR970705988A (ko) 연골 조직의 이상에 기인하는 질환의 예방 또는 치료제(Preventive or remedy for diseases caused by abnormalities in cartilage tissues)
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
TR200100333T2 (tr) Bir karnitin ve bir karotenoit içeren antioksidan, antiproliferos bileşim
HUP0104347A2 (hu) Propionil-L-karnitint és egy flavonoidot tartalmazó antioxidáns készítmény, amely a trombózis és az ateroszklerózis kezelésében alkalmazható
US20050182037A1 (en) Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof
ATE422883T1 (de) Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden
TNSN00150A1 (fr) Composition cardioactive comprenant l-carnitine et ses derives et des extraits d'aubepine (crataegus)
DE60103854D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von lipidstoffwechselstörungen und allergischen formen
BR0014614A (pt) Composição e seus usos, método para redução da inflamação em um paciente, método para redução dos nìveis de fibrinogênio no soro e método para redução ou prevenção do inìcio de artrite reumatóide e osteoartrite
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica

Legal Events

Date Code Title Description
8364 No opposition during term of opposition